Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.
about
Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.Don't stress about CRF: assessing the translational failures of CRF1antagonists.Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view.Role of Corticotropin-releasing Factor Signaling in Stress-related Alterations of Colonic Motility and Hyperalgesia.The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats.High fat diet decreases beneficial effects of estrogen on serotonin-related gene expression in marmosets.Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study.Evaluating psychological interventions in a novel experimental human model of anxietyAcid-base dysregulation and chemosensory mechanisms in panic disorder: a translational updateThe effect of citalopram on midbrain CRF receptors 1 and 2 in a primate model of stress-induced amenorrhea.The effect of long-term ovariectomy on midbrain stress systems in free ranging macaques.The effect of short moderate stress on the midbrain corticotropin-releasing factor system in a macaque model of functional hypothalamic amenorrhea.Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD).Novel investigational therapeutics for panic disorder.Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.Neuropeptide systems and new treatments for nicotine addiction.Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets.Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function.Human fear acquisition deficits in relation to genetic variants of the corticotropin-releasing hormone receptor 1 and the serotonin transporter--revisited.Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO2 challenge.Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population.The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.
P2860
Q27014879-A4C22039-38AF-4BE7-A028-BCE161B8BEDBQ30387331-BAB01B3E-9C35-4C9F-A48E-94576D3A95E4Q30399543-3710FE99-B1E5-4860-80A2-D592943D6CD0Q30459616-1E760F0E-E33D-4723-A1B1-93EA63382C88Q34882307-CF38DF4B-5B34-4B73-9E67-10C5DF38BFC7Q34989237-5EF85F3F-55F9-4E21-A7F5-A00E9CF2FCE8Q35117855-4FB48BC7-5A03-445D-B0E0-0CDE26023F5CQ35161361-CE3DAD7D-2F95-42EC-B735-700269951697Q35527749-A6581B74-2109-4030-A495-B44A75CACE45Q35753229-EC762D09-48BE-47C3-83FA-24ECC5281674Q36225978-A6C1808D-60AE-445C-AE9F-BC5C614111D6Q36409560-8D1399B2-6D9B-4538-B1F9-7954BBB0112DQ37653080-71CFFF31-03FD-487A-B7A9-C7D867B1B7B3Q37670707-70689D2F-50BC-4AF6-BB64-750BDB165ED6Q37686937-96307F5F-928E-4C1E-B83B-EED2B75B124FQ37945155-DB9C5930-39BC-45D0-9AE6-6288244F83B4Q38300166-BEC1C40B-F4C2-4E10-9FE4-3D17D396F09FQ38631796-77B6C5DD-E6BB-4DE4-8543-853F80A3A624Q39059946-3968CFDB-983B-4B34-A33F-CEC661A96F86Q39183229-D99DE587-2689-4462-9E28-DF3811E7B58EQ44130094-560329B4-8D87-4907-8465-E20D723DA217Q47611691-00796A24-7134-4D85-8E18-BDB06B9D3518Q47971036-9A86F6C2-834D-4DF8-BC25-8D632370883FQ48705554-94985A40-5692-42A7-8D29-B593DCDA20C4Q50555256-B268BF48-4E7F-4DAA-9D97-77B058241DFAQ50582409-F1EA1272-B896-47ED-8DA9-F0F06CA05DE0Q52148833-B7ADAF3F-5773-46F0-BCAE-87B2C7979C51
P2860
Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Preliminary evidence of anxiolytic effects of the CRF
@nl
Preliminary evidence of anxiol ...... mental model of human anxiety.
@en
type
label
Preliminary evidence of anxiolytic effects of the CRF
@nl
Preliminary evidence of anxiol ...... mental model of human anxiety.
@en
prefLabel
Preliminary evidence of anxiolytic effects of the CRF
@nl
Preliminary evidence of anxiol ...... mental model of human anxiety.
@en
P2093
P2860
P50
P356
P1476
Preliminary evidence of anxiol ...... mental model of human anxiety.
@en
P2093
Alison Diaper
Andreas Papadopoulos
Gerard R Dawson
Me Schmidt
P van der Ark
Suzanne Phillips
P2860
P304
P356
10.1177/0269881111400650
P407
P577
2011-05-09T00:00:00Z